08-22-02

**Application Number** 

Filing Date

09/779,791

同

02/08/2001

08/20/2002

AUG 2 0 2002 Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE perwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. THE TO DEMOND

**TRANSMITTAL** 

FORM		First Named Inventor	Jon A. Wolff	H CE		
(to be used for all correspondence after initial filling)		Group Art Unit		HI '		
		Examiner Name		VIER 1600/29		
Total Number of Pages in This Submission 13		Attorney Docket Number	Mirus.006.03	600/25		
	ENCL	OSURES (check	all that apply)	8		
Fee Transmittal Form		nent Papers A <i>pplication)</i>	After Allowance Commun to Group	nication		
Fee Attached	Drawing	g(s)	Appeal Communication t of Appeals and Interferen			
✓ Amendment / Reply	Licensin	ng-related Papers	Appeal Communication t			
After Final	Petition	•	Proprietary Information			
Affidavits/declaration(s)			Status Letter			
Extension of Time Request	Change Address	of Attorney, Revocation e of Correspondence s al Disclaimer	Other Enclosure(s) (pleatidentify below):	ase		
Express Abandonment Request		st for Refund				
Information Disclosure Statement	CD, Nu	mber of CD(s)				
Certified Copy of Priority Document(s)	Remarks					
		nent pages	ina			
Response to Missing Parts under 37 CFR 1.52 or 1.53		containing Seq. List sion of Seq. Listing	_			
				<u> </u>		
		CANT, ATTORNEY, OR A	AGENI			
Firm Mark K. Journal Individual name	ohnson		,			
Signature M						
Date	08/20/2002					
CERTIFICATE OF MAILING						
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date:  August 20, 2002						
Typed or printed name Mark K	. Johnson					

Date

Signature



UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office
COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

SERIAL NUMBER FILING DA	TE FIRST NAMED APPLICAN	T ATTORNEY DOCKET NO.
09/779,791 02/08/200	1 Wolff et al.	MIRUS.006.03

### RECEIVED

AUG 2 6 2002

TECH CENTER 1600/2900

EXA	MINER
Sita S.	Pappu
ART UNIT	PAPER NUMBER
1636	5

### Please find below a communication from the EXAMINER in charge of this application

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821-1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

- 1). Sequences are disclosed in the specification but are not identified by their sequence identifiers (i.e. SEQ ID NO). For example, pages 26 AND 35 disclose amino acid sequences that are not identified by sequence identifiers. Applicant is further reminded that amendment to the specification, and/or claims is required to comply with 37 C.F.R. 1.821(d). Each sequence disclosed in the specification and figures must be identified by its sequence identifier (i.e., SEQ ID NO:). Applicant is reminded that the entire specification and figures should be reviewed for sequence disclosures.
- 2). NO CRF was submitted for the sequences disclosed. An initial CRF, and a paper copy are required along with a statement that the paper copy and CRF are identical.

APPLICANT IS GIVEN 30 days FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.R.F. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Examiner Sita S. Pappu whose telephone number is (703) 305-5039. If the examiner cannot be reached, inquiries can be directed to Supervisory Patent Examiner Irem Yucel whose telephone number is (703) 305-1998. The fax number for the organization where this application is assigned is (703) 308-8724. Any inquiry of a general nature or relating to the status of this application should be directed to the Patent Analyst at (703) 305-2982.

ANNE-MARIE BAKER
PATENT EXAMINER

Application N	09/779,791
	· <u> </u>

# NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which th Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comp with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):



- 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- 7. Other:Sequences are disclosed in the specification but are not identified by their sequence identifiers (i.e. SEQ ID NO). Applicant is reminded that the entire specification and figures shoul be reviewed for sequence disclosures. Applicant is further reminded that amendment to the specificatio and/or figures is required to comply with 37 C.F.R. 1.821(d).

#### **Applicant Must Provide:**

An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".

An <u>initial</u> or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry in the specification.

A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact: RECEIVED For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

Patentin Software Program Support

Technical Assistance......703-287-0200

To Purchase Patentin Software......703-306-2600

TECH CENTER 1600/2900

AUG 2 6 2002

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

09/03/2002 11:21

2627923919

GTI:



## TO: TRACEY JOHNSON, FAX: 703.746.3412

		Application Number	09/779,791
TRANSMITTAL		Filing Date	February 8, 2001
FORM F		First Named Inventor	Wolff
(to be used for all correspondence after i	initial filing)	Group Art Unit	
		Examiner Name	
Total Number of Pages in This Submiss	ion 3	Attorney Docket Number	Mirus.006.03
	ENCLOS	SURES (check all that app	(y)
Fee Transmittel Form	Assignm (for an A	nent Papers Application)	After Allowance Communication to Group
Fee Attached	Drawing(s)		Appeal Communication to Board of Appeals and interferences
Amendment / Response	Licensing-related Papers		Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
After Final	Petition Routing Slip (PTO/SB/89) and Accompanying Petition		Proprietary Information
Affidavits/declaration(s)	Petition to Convert to a Provisional Application		Status Letter
Extension of Time Request	Power of Attorney Revocation		Additional Enclosure(s) (please identify below):
	Address Termina	l Discleimer	(please defining section).
Express Abandonment Request	Small E	ntity Statement	
Information Disclosure Statement	Reques	t for Refund	
_, `` <u>L</u>	Remarks		
Response to Missing Parts/ Incomplete Application			
Response to Missing Parts under 37 CFR			
1.52 or 1.53	****		
	OF APPLIC	CANT, ATTORNEY, OR A	GENT
Mark K. Johnson	<b></b>		
Signature	lact	Juna	
September 2, 200	1	•	7
	CERTIFICA	TE OF MAILING	
nereby certify that this correspondence is a velope addressed to: Assistant Commiss	being deposite	ed with the United States Pos nts, Weshington, D.C. 20231	tal Service as <u>express mall In an</u> 另外格 <del>分的</del> 产于第二 <u>年的明明的和 88888882</u> 1977
yped or printed name   Mark K. John			1 FC:215